Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge

Neurol Sci. 2023 Apr;44(4):1141-1146. doi: 10.1007/s10072-023-06609-y. Epub 2023 Jan 12.

Authors

Maria D'Apolito¹, Marianna G Rispoli², Paola Ajdinaj², Anna Digiovanni², Valentina Tomassini^{2

3}, Luigia Gentile⁴, Giovanna De Luca^{2

3}

Affiliations

¹ Department of Neuroscience, Imaging, and Clinical Sciences, "G. D'Annunzio" University of Chieti-Pescara, Chieti, Italy. maria.dapolito93@gmail.com.
² Department of Neuroscience, Imaging, and Clinical Sciences, "G. D'Annunzio" University of Chieti-Pescara, Chieti, Italy.
³ Department of Neurology, "SS. Annunziata" University Hospital, 66100, Chieti, Italy.
⁴ Department of Radiology, University "G. D'Annunzio" of Chieti, Chieti, Italy.

No abstract available

Publication types

Letter

MeSH terms

COVID-19 Testing
COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Chronic Disease
Humans
Leukoencephalopathy, Progressive Multifocal* / diagnostic imaging
Leukoencephalopathy, Progressive Multifocal* / etiology
Multiple Sclerosis*
Natalizumab

Substances

COVID-19 Vaccines
Natalizumab